CoChat

CIP2A Is Associated with Human Breast Cancer Aggressivity

Open access

Published version of a preprint

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Purpose: To investigate the clinical relevance of the recently characterized human oncoprotein cancerous inhibitor of protein phosphatase 2A (CIP2A) in human breast cancer. Experimental Design: CIP2A expression (mRNA and protein) was measured in three different sets of human mammary tumors and compared with clinicopathologic variables. The functional role of CIP2A in breast cancer cells was evaluated by small interfering RNA–mediated depletion of the protein followed by an analysis of cell proliferation, migration, anchorage-independent growth, and xenograft growth. Results: CIP2A mRNA is overexpressed (n = 159) and correlates with higher Scarff-Bloom-Richardson grades (n = 251) in samples from two independent human breast cancer patients. CIP2A protein was found to be overexpressed in 39% of 33 human breast cancer samples. Furthermore, CIP2A mRNA expression positively correlated with lymph node positivity of the patients and with the expression of proliferation markers and p53 mutations in the tumor samples. Moreover, CIP2A protein expression was induced in breast cancer mouse models presenting mammary gland–specific depletion of p53 and either BRCA1 or BRCA2. Functionally, CIP2A depletion was shown to inhibit the expression of its target protein c-Myc. Loss of CIP2A also inhibited anchorage-independent growth in breast cancer cells. Finally, CIP2A was shown to support MDA-MB-231 xenograft growth in nude mice. Conclusions: Our data show that CIP2A is associated with clinical aggressivity in human breast cancer and promotes the malignant growth of breast cancer cells. Thus, these results validate the role of CIP2A as a clinically relevant human oncoprotein and warrant further investigation of CIP2A as a therapeutic target in breast cancer treatment. (Clin Cancer Res 2009;15(16):5092–100)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-08-3283

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 233

Metadata

Authors
Côme, C., Laine, A., Chanrion, M., Edgren, H., Mattila, E., Liu, X., Jonkers, J., Ivaska, J., Isola, J., Darbon, J.-M., Kallioniemi, O., Thézenas, S., & Westermarck, J.
Affiliations
  • Authors' Affiliations: 1Centre for Biotechnology, University of Turku and Åbo Akademi University; 2VTT, Technical Research Centre, Turku, Finland; 3Institut de Recherche en Cancérologie de Montpellier, CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France; 4Institute for Molecular Medicine Finland, University of Helsinki, Finland; 5Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; and 6Institute of Medical Technology, University of Tampere, and Tampere University Hospital, Tampere, Finland
  • Åbo Akademi University (FI)
Corresponding author
Westermarck, Jukka
Venue
Clinical Cancer Research
Published
2009-08-12
Volume
15
Issue
16
Pages
5092-5100
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2111614147
Cited by
221
References
22
Citations by year
2026: 1 · 2025: 5 · 2024: 1 · 2023: 8 · 2022: 3 · 2021: 8 · 2020: 15 · 2019: 14 · 2018: 13 · 2017: 21 · 2016: 16 · 2015: 23 · 2014: 22 · 2013: 24 · 2012: 19
FWCI
11.04
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Institut Bergonié
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords
CIP2A, breast cancer, oncoprotein, tumor aggressiveness, protein phosphatase 2A inhibitor, p53 deficiency, BRCA1, BRCA2, c-Myc, lymph node metastasis, tumor grade, anchorage-independent growth, xenograft tumor growth, therapeutic target
MeSH terms
Adult, Aged, Aged, 80 and over, Animals, Autoantigens, Breast Neoplasms, Carcinoma, Female, Humans, Genetic Linkage, Membrane Proteins, Middle Aged, Neoplasm Invasiveness, Neoplasm Metastasis, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Xenograft Model Antitumor Assays, RNA, Small Interfering, Intracellular Signaling Peptides and Proteins, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CIP2A Is Associated with Human Breast Cancer Aggressivity. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-08-3283
The paper
Côme, C., Laine, A., Chanrion, M., Edgren, H., Mattila, E., Liu, X., Jonkers, J., Ivaska, J., Isola, J., Darbon, J.-M., Kallioniemi, O., Thézenas, S., & Westermarck, J. (2009). CIP2A Is Associated with Human Breast Cancer Aggressivity. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-08-3283

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.